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Bacterial infections promote important alterations in im-
mune, hemodynamic, and metabolic function which can result
in irreversible shock. These changes are mediated by host-
secreted cytokines rather than by direct action of the endotoxin
lipopolysaccharide (LPS) derived from the cell wall of bacteria.
One cytokine that has been extensively studied for its role in
infection is macrophage-derived tumor necrosis factor alpha
(TNFa) [I]. Three observations suggest that TNFc has a
central involvement in endotoxic shock: (i) High levels of
TNFa can be found in blood of animals and humans with
endotoxic shock; (ii) When injected to animals, TNFa causes a
syndrome similar to endotoxic shock, with hypotension, de-
creased tissue perfusion, organ failure, and lactic acidosis; (iii)
The effects of LPS can be prevented by prior passive immuni-
zation of animals with polyclonal or monoclonal antibody
directed against TNFa.
During severe bacterial infections, acute renal insufficiency
occurs frequently and contributes significantly to the morbidity
and mortality of the shock. In vivo studies indicate that LPS
induces an increase in renal vascular resistance and a decrease
in glomerular filtration rate [2]. A variety of mediators could
contribute to these hemodynamic changes. They include: ara-
chidonic acid metabolites (thromboxane A2, TXA2; leuko-
trienes, LT), platelet activating factor (PAF), adenosine, cate-
cholamines, angiotensin II and cytokines. Their synthesis is
probably initiated by the release of TNFa [3]. The present
paper discusses the cellular origin of TNFa within the kidney,
and reviews the mechanisms whereby factors released in re-
sponse to TNFa participate in controlling the secretion of this
cytokine.
Cellular source of TNFa within the kidney
Autoradiography studies using radiolabeled endotoxin indi-
cate that i.v, injected LPS is rapidly concentrated in the
phagocytic vacuoles of hepatic Kupifer cells, splenic macro-
phages and leukocytes [4]. Lower concentrations are observed
in the kidneys. Nevertheless, after injection of unlabeled endo-
toxin, Northern blotting studies demonstrate that TNFa mRNA
expression in the kidney increases to a greater extent and for a
longer period of time than in other tissues, including the liver
[5]. The precise location of TNFa mRNA in the kidney has not
been determined in this study, but could include both glomer-
ular or tubular cells and blood-borne cells. Because animals
injected with LPS develop a transient influx of neutrophils into
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glomerular capillaries [6], these cells could participate in the
renal expression of TNFa mRNA. In accordance with this
hypothesis, it has been shown that purified circulating human
blood granulocytes release TNFc after in vitro stimulation with
LPS [7]. In another in vitro study [8], the ability of proximal
tubular epithelial cells to express TNFa transcripts has been
assessed. These cells, which have been cultured from renal
cortical tubules after transformation with origin-defective SV 40
DNA, do not express TNFa mRNA when unstimulated. How-
ever, stimulation by interleukin-l (IL-i) and, to a lesser extent
by LPS, induces TNFa transcripts.
To define whether resident glomerular cells contribute signif-
icantly to TNFa generation in the kidney, we investigated the
capacity of glomeruli isolated from rats given LPS i.v. injection
to release TNFa bioactivity (Fouqueray, unpublished observa-
tion). Before LPS injection, glomerular cells do not spontane-
ously release TNFa activity as determined by L-929 fibroblast
lytic assay. In contrast, glomeruli isolated from rats given LPS
release TNFa activity into the medium. The rate of this
production, which increases transiently, appears to be related
directly to the dose of LPS (between 10 and 200 ig per kg of
body weight) and to the lag period between LPS injection and
glomerular isolation (20 to 60 mm). Higher concentrations of
LPS and longer periods of time produce no further increase in
TNFa bioactivity. This cytotoxic activity appears to be anti-
genically related to TNFc since: i) the in vitro addition of rabbit
anti-mouse recombinant TNFa polyclonal antibody completely
neutralizes it; and ii) production of TNFc is also measured in
the supernatant of isolated glomeruli using an enzyme-linked
immunosorbent assay (ELISA). In fact, time course studies
show that the peak of TNFa production is delayed when
compared with that of TNFa bioactivity, suggesting that TNFs
molecules are progressively inactivated. The appearance of
TNFa is followed by that of interleukin-6 (IL-6), another
cytokine that has also been suggested to play a role in acute
infection. By contrast, no IL-I activity can be detected.
To determine whether glomerular cells respond directly to
LPS or rather are a target for substances released from extra-
renal tissues exposed to LPS, glomeruli isolated from control
rats have been incubated in vitro with LPS. Results show that
in vitro added LPS promotes a dose-dependent (10 ng to 10
gIml) increase of TNFc release which is similar to that
induced by in vivo challenge. To address the issue of tissue
macrophage contamination, rats have been irradiated with 900
rads five days before glomeruli have been isolated. Under these
conditions, glomeruli are depleted of bone marrow-derived
phagocytes [9]. However, there is no significant difference in
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TNFa production by glomeruli isolated from the kidneys of
irradiated or control rats. This indicates that the presence of
monocytes/macrophages within the glomerular capillaries does
not account for the observed results.
This prompted us to investigate the ability of resident mesan-
gial cells to express TNFa mRNA, and to produce TNFa.
Northern blot analysis indicates that TNFa mRNA is weakly
expressed in unstimulated rat mesangial cells [10]. In LPS-
activated cells, TNFa gene expression is characterized by two
hybridizing bands: one strongly hybridizing band and a second
weaker band of higher molecular weight, which could represent
a precursor to the main TNFs mRNA. In these cells, cell-
associated TNFc activity is demonstrable after less than one
hour exposure to LPS, peaks at two hours and decreases
progressively thereafter, while TNFa activity increases in the
medium [10, 11]. The rise of TNFa activity in the medium is
followed after nine hours by a progressive decay. TNFa release
from cultured rat mesangial cells is similarly induced by viruses
and environmental lectins [12].
Flow cytometry experiments and immunohistochemical stud-
ies using immunogold silver staining technique reveal that two
thirds of LPS-activated mesangial cells exhibit TNFa expres-
sion at their surface, The greatest part of these cell-associated
TNFa molecules persist after low pH treatment, indicating that
they are integral membrane proteins and not molecules attached
to cell surface receptors [11]. The presence of membrane-
associated and soluble TNFa has been also assessed by immu-
noblotting. The integral membrane TNFa has been identified as
the 26 kDa molecule described previously on monocytes [13],
whereas the released forms of TNFa are 17 kDa molecules. The
time lag between the expression of membrane-associated TNFa
and the secretion of TNFa into the medium following mesangial
cell exposure to LPS, and the temporal association between the
decay of membrane-associated TNFa activity and the rise of
TNFa activity in the medium suggest that the release of 17 kDa
TNFa depends for one part on the cleavage of the integral
membrane 26 kDa molecules. This process could be mediated
by the activation of metalloproteinases, the identity of which is
still to be established.
In summary, TNFa has multiple potential cellular sources in
the kidney during endotoxic shock; they include blood-borne
cells, glomerular mesangial cells and tubular epithelial cells.
Effects of TNFa on mesangial cells
T. Bertani et al [14] have studied the glomerular structural
changes induced by i.v. infusion of TNFa in the rabbit. The
main finding is the presence of endothelial cell swelling, poly-
morphonuclear leukocyte accumulation and fibrin formation in
the capillaries. Glomeruli from rats injected with TNFa also
show a transient influx of neutrophils into capillaries but no
formation of thrombi [6]. Nevertheless, TNFo administration to
rats with antiglomerular basement-membrane antibody-medi-
ated nephritis causes a substantial amplification of the glomer-
ular injury characterized by intra-capillary thrombi and endo-
thelial cell swelling.
There are a number of different ways whereby TNFc might
affect the structure and function of glomerular cells, and espe-
cially of mesangial cells. They have been identified in in vitro
studies.
Synthesis of prostaglandins (PG) and PAF
TNFa either alone or synergistically with IL-I increases the
mesangial synthesis of PGE2, PGE2 and 6-keto-PGF1, the
stable breakdown product of PGI2 [15—17]. Because TNFa
increases the release of a phospholipase A2 activity and of
arachidonic acid and induces a cyclooxygenase activity, it
appears to act at two distinct levels. In addition to stimulating
the production of PGs by mesangial cells, TNFc also induces
mesangial cells to produce PAF [18] which remains mainly
cell-associated. Its synthesis is responsible for changes in cell
shape and cytoskeletal organization suggesting cell contraction.
Formation of cyclic nucleotides
TNFa stimulates cyclic AMP accumulation in the mesangial
cell culture medium [15]. Because indomethacin suppresses the
effect of TNFa on PGs but only reduces that on cyclic AMP, it
is likely that TNFc stimulates cyclic AMP levels in part
independently of its effect on PG production.
TNFa also stimulates cyclic GMP formation by bovine [19]
and murine [20] mesangial cells. N-monomethyl-L-arginine
decreases TNFa-induced cyclic GMP accumulation, an effect
that is reversed by L-arginine. These data suggest that, upon
TNFa challenge, the NO-producing L-arginine pathway is
activated in mesangial cells with a subsequent increase in cyclic
GMP levels.
Release of reactive oxygen metabolites
In response to TNFa, human mesangial cells are able to
generate reactive oxygen metabolites (superoxide anion and
hydrogen peroxide) in amounts comparable to those produced
by monocytes [21]. Moreover, on treatment with TNFa, murine
mesangial cells exhibit an upregulated expression of intercellu-
lar adhesion molecule-I (ICAM-l), an adhesion molecule for
neutrophils and lymphocytes [22]. Because TNFa has been
found to also affect neutrophil function by increasing the
expression of the C3bi receptor/adherence glycoprotein (CD 11
complex), and by stimulating the production of hydrogen per-
oxide, both mesangial cells and adherent neutrophils could
contribute to the TNFa-induced generation of reactive oxygen
metabolites within the glomerulus.
Regulation of coagulation-related functions
It is now well established that mesangial cells produce a small
amount of tissue factor-like procoagulant activity that is stim-
ulated by cell exposure to TNFa [23]. The second major effect
of TNFa on glomerular cells is to decrease the expression of
thrombomodulin (Kanfer, personal communication). All these
effects result in a shift of the balance between procoagulant and
anticoagulant molecules towards fibrin formation and possibly
thrombosis.
Cell proliferation
There are published reports both of TNF-mediated en-
hancement and of TNFa-mediated inhibition of mesangial cell
proliferation. TNFa causes a significant increase of DNA
synthesis by human mesangial cells [24], when cultured in
serum-free medium. By contrast, TNFa does not affect [15] or
even inhibit [25] growth of proliferating rat mesangial cells. The
origin of this discrepancy could be that, in serum enriched
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medium, the endogenous PG production simultaneously in-
duced by TNFa antagonizes its growth promoting effect. In-
deed, coincubation of proliferating mesangial cells with TNFs
and indomethacin is associated with an increase of DNA
synthesis [26].
In summary, TNFa has multiple actions on mesangial cells
that could locally promote hemodynamic changes and inflam-
matory responses.
Regulation of TNFx release from LPS-activated meson gial
cells
Recent investigations have shown that LPS-stimulated TNFa
release is reduced by PGE2 [10]. Indeed, exposure of mesangial
cells to LPS causes the production of TNFa as well as that of
PGE2, and treatment of these cells by indomethacin promotes
both inhibition of PGE2 synthesis and stimulation of TNFa
production. The inhibitory effect of PGE2 is confirmed by the
observation that TNFa release is reduced in the presence of
exogenous PGE2 at doses ranging between 10 and 100 nM.
Additionally, exogenous PGE2 induces an increase of cyclic
AMP production by mesangial cells treated with LPS and
indomethacin, and 8-bromo-cyclic AMP promotes a dose-de-
pendent reduction of TNFa synthesis under identical condi-
tions [10]. These observations imply that cyclic AMP is the
intracellular messenger for PGE2.
There is also in vitro evidence of effects of reactive oxygen
metabolites on the release of TNFs from LPS-activated mesan-
gial cells [11]. We have demonstrated that desferrioxamine
(DFX), an iron chelator preventing the synthesis of hydroxyl
radicals via the Haber-Weiss reaction, dose-dependently de-
creases this process. Time course studies indicate that there is
first a delayed release of the cytokine, and then an acceleration
of its inactivation. After a short period of incubation with LPS,
the release of TNFcs into the medium is reduced by DFX,
whereas the expression of TNFa increases significantly at the
cell surface [11]. One possibility for the DFX effect might be
that this drug prevents the generation of hydroxyl radical and
hence indirectly interferes with the cleavage of membrane-
associated TNFa. Indeed, hydroxyl radical could enhance this
cleavage by increasing the susceptibility of the cytokine to
proteolytic damage, by inactivating protease inhibitors, or by
activating latent metalloproteinases. When measured in the
culture medium of LPS-activated mesangial cells after longer
periods of incubation, TNFa activity appears to decline faster
in the presence of DFX than under control conditions. There is
recent evidence that inactivation of the TNFr molecule could
result in part from its interaction with TNFa binding proteins,
identified as truncated soluble forms of membrane-associated
TNFa receptors [27]. These molecules undergo oxidative dam-
age when exposed to reactive oxygen metabolites [28, 29]. Thus
the major hypothesis to explain DFX-mediated increases in
TNFa inactivation is that DFX prevents the degradation of
soluble TNFa binding proteins [29].
In vitro experiments indicate that exposure of cells to ele-
vated temperature leads to the synthesis of a small number of
heat shock proteins, and to the suppression of many other
proteins [30]. Because fever is induced by TNFa as by other
cytokines, studies have been conducted in our laboratory to
elucidate the involvement of elevated temperatures in the
regulation of TNFa production by glomerular cells (Amrani,
unpublished observation). Exposure of these cells to elevated
temperatures (39 to 43°C) for 20 minutes decreases the subse-
quent LPS-induced TNFa release. The effect is maximal when
LPS is added zero to two hours after the heat shock, and then
progressively declines to be undetectable after 24 hours. This
heat induced decrease in TNFa release is associated with
decreased expression of membrane-associated TNFa.
In summary, TNFx has multiple actions on mesangial cells
and on distant target cells (that is, brain) that appear to promote
in turn either amplification or limitation of TNFa generation.
The importance of PGs, cyclic AMP, reactive oxygen metabo-
lites, and elevated temperatures is well established. That of
NO, cyclic GMP and coagulation products remains to be
investigated.
Conclusion
This review has emphasized the role of mesangial cells in the
generation of TNFa within the kidney because of the evidence
of its occurrence in vitro. However, it is likely that with further
study additional cellular sources may prove to be equally
important.
Evidence is accumulating that local and transient production
of TNFx may benefit the host, whereas generalized or sustained
production may be harmful [311. Therefore, pharmacologic
interventions effective in blocking the release of soluble 17 kDa
TNFa molecule by preventing the cleavage of the integral
membrane 26 kDa molecule would be of interest. Mesangial
cells under controlled culture conditions would represent a
useful tool for studies in this area.
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